Background: The absence of transthyretin (TTR) in AD mice decreases brain Aβ clear-
vious study demonstrated TTR participation in Aβ transport from the brain to the liver. 18 In that study, we showed that TTR promotes Aβ internalization and efflux in a human cerebral microvascular endothelial cell line, hCMEC/D3, used as an in vitro BBB model. TTR also stimulated brain-to-blood Aβ permeability in these cells, suggesting that TTR interacts directly with Aβ at the BBB. We then showed that TTR crosses the monolayer of cells only in the brain-to-blood direction, as confirmed by in vivo studies, proposing that TTR can transport Aβ from, but not into, the brain. Moreover, TTR increased Aβ internalization by SAHep cells (human hepatoma cells) and by primary hepatocytes derived from TTR+/+ mice when compared to TTR−/− animals.
Interestingly, TTR also regulates LRP1 receptor levels, as lower receptor expression was found in brains and livers of TTR−/− mice and in cells incubated without TTR.
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There are several studies reporting that TTR levels are diminished both in the CSF 19 and in the plasma 8 of patients with AD, found to occur early in the disease development. 20 However, the cause of TTR reduction in AD is not known yet, but stability of its tetramer structure seems to play a significant role, leading to the stability hypothesis which postulates that an unstable TTR is cleared faster, thus explaining the lower levels. In fact, it has also been shown that plasma TTR from patients with AD presents impaired ability to carry T4 hormone.
As T4 binding to TTR implies tetrameric conformation, this indicates TTR instability and supports the idea that the TTR tetramer is the main Aβ-binding species. 20 Furthermore, studies using TTR mutants showed that the lower the stability of TTR variant (and the higher its amyloidogenic potential), the weaker its affinity toward Aβ42; thus, the highly unstable TTR with a leucine substituted by a proline at position 55 (L55P TTR) was shown to bind weakly to Aβ.
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Although some screening studies in patients with AD demonstrated no significant correlation between TTR variants and AD, 22 a very recent report showed a tendency of enrichment in six TTR rare variants in patients with AD in Han Chinese population. 23 Also, in another recent genebased analysis, some TTR variants were reported to be associated with AD. 24 Regardless of the possible genetic relationship between AD and TTR variants, other factors, including conformational changes resulting from aging, metal ions concentration, or interaction with other proteins, may also influence TTR stability, levels, and binding properties toward Aβ.
Most importantly, small compounds known to stabilize TTR tetrameric fold have been demonstrated to improve TTR-Aβ interaction, in vitro. 25 One of such stabilizers, iododiflunisal (IDIF), when administrated to AD transgenic mice ameliorates AD features, such as cognitive function, brain Aβ deposition, and plasma Aβ levels. 26 Moreover, oral administration of resveratrol, another TTR stabilizer present mainly in the grape skin, reduced significantly brain Aβ levels and amyloid deposits, increased LRP1 protein expression in both brain and liver of the AD mice, and increased TTR plasma levels.
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Therefore, this study aimed to unravel the importance of TTR stability in Aβ clearance and LRP1 expression levels at the BBB and the liver, both by comparing the effects of human recombinant wild-type TTR (WT TTR) versus L55P TTR and by studying the impact of stabilizing L55P TTR using IDIF or resveratrol in this process.
| MATERIALS AND METHODS

| Recombinant TTR production, purification, and labeling
WT and L55P TTR were produced in a bacterial expression system using Escherichia coli BL21 and purified as previously described. 28 Briefly, after growing the bacteria, the protein was isolated and purified by preparative gel electrophoresis after ion-exchange chromatography. Protein concentration was determined by the Bradford method (Bio-Rad Hercules, CA, USA), using bovine serum albumin as standard.
When appropriate, WT TTR and L55P TTR were labeled with Alexa
Fluor 633, using the Alexa Fluor ® 633 Protein Labeling Kit (Molecular probes, alfagene, Carcavelos, Portugal), following the manufacturer's instructions.
| Animals
In this work, TTR-wild-type mice carrying both copies of the TTR gene (TTR+/+), TTR-heterozygous mice (TTR+/−), and TTR-knockout mice (TTR−/−) in a SV129 background 29 were used. These mice were obtained from the littermate offspring of heterozygous breeding pairs.
The AD mouse model used in this study was generated by crossing APPswe/PS1A246E transgenic mice purchased from The Jackson Laboratory with TTR−/− mice, as previously described. 16 In this proj- 
| Blood collection from mice and human subjects
Mice were profoundly anesthetized with an anesthetic combination of ketamine (75 mg/Kg) and medetomidine (1 mg/Kg) by intraperitoneal injection. Blood was collected from the inferior vena cava with syringes with EDTA, followed by centrifugation at 1000 rpm for 15 minutes at room temperature (RT). Supernatant was collected and frozen at −80°C until used.
Patients with AD (study group) were recruited at the Dementia Clinic, Neurology Department, Centro Hospitalar e Universitário de Coimbra, and blood was obtained by peripheral venipuncture. This study was approved by the ethics board, and all subjects or responsible caregivers, whichever appropriate, gave their informed consent.
The control healthy group matched for age and gender with the study group included subjects without neurological or psychiatric history and no cognitive impairment and was recruited at LabMed Center. All subjects were informed on the purpose of the study and gave their written consent. These samples were already available in the laboratory and were used in a previously reported work. 
| Evaluating tetramer stability of human plasma TTR
To evaluate TTR tetramer stability, an assay employing urea-mediated denaturation was used as previously described in the literature 30, 31 with minor alterations. In this assay, the extent of denaturation of plasma TTR of control (n=10) and AD (n=10) human subjects was assessed by evaluating levels of folded TTR (tetramer, trimer, and dimer) versus the levels of monomer. Briefly, 3 μL of plasmas was incubated overnight with urea (6 mol L −1 ), then cross-linked by 25% glutaraldehyde (4 minutes) and quenched by the addition of NaBH 4 (7% in 0.1 mol L −1 NaOH). SDS reducing gel loading buffer (SDS final concentration = 2%) was then added and samples were boiled for 5 minutes. Proteins were then separated using 13.5% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membrane (Whatman™ GE Healthcare, Chalfont St. Giles, UK, Protan BA 83) using a wet system (Bio-rad Criterion Blotter). The membrane was cut to separate the monomeric from folded TTR as the latter always comprised the larger part of the sample, and the signal was much stronger than for monomeric TTR, needing different exposure times. The membranes were then blocked for 1 hour at room temperature with 5% powdered skimmed milk in PBS containing 0.05% Tween-20 (PBS-T).
Immunoblotting was then performed using anti-TTR antibody (DAKO, Glostrup, Denmark, 1:2000) to detect folded and monomer TTR. The blots were developed using Clarity™ Western ECL substrate (Bio-Rad), and proteins were detected and visualized using a chemiluminescence detection system (ChemiDoc, Bio-Rad). Images were analyzed and band intensities were quantified using Image Lab (Bio-Rad, version 4.1).
| Cell lines and primary hepatocytes culture
The immortalized human cerebral microvascular endothelial cell line Primary hepatocytes were isolated from livers of TTR+/−, TTR−/−, or AD/TTR +/− mice with 3 months of age. To obtain these cells, twostep collagenase perfusion of liver was performed as previously described in detail. 18 Briefly, a cannula was inserted into the portal vein and perfusion medium and then collagenase solution were allowed to perfuse through the liver. The entire perfused liver was then removed to a Petri dish containing isolation medium proceeding to the next steps of filtering and centrifugations of cell suspension, counting live cells, and seeding with attachment medium for 3 hours. Then, the medium was changed to stimulation medium. After 24 hours, the medium was renewed and after 48 hours, the experiments were performed as will be described later.
| Flow cytometry analysis of Aβ and TTR cellular internalization
To study Aβ and TTR uptake, hCMEC/D3 or HepG2 cells were grown to 80% confluence in 24-well plates. Cells were incubated with 500 ng/mL 632/580 nm; emission: 647 nm). Furthermore, TTR and Aβ inside the same cells were also analyzed using microscopy as will be described.
| hCMEC/D3 cells permeability to Aβ and TTR
| Immunofluorescence for Aβ, TTR, or LRP1
hCMEC/D3, HepG2 cells, or primary hepatocytes (AD/TTR +/−) were grown on glass coverslips (Thermo Scientific, Boston, MA, USA) precoated with rat tail collagen type I solution.
To observe internalization of Aβ and TTR, HepG2 cells were incubated with FAM-Aβ and/or WT or L55P TTR-633 for 1 hour, washed with PBS, and fixed with acetone for 7 minutes in −20°C. After wash, coverslips were then mounted with Fluoroshield™ with DAPI (Sigma-Aldrich).
To assess the effect of TTR stability on LRP1 protein levels, 
| Study of lysosomal activity using Lysotracker deep red
To study the lysosomal activity and the fate of Aβ, HepG2 cells were seeded in 24-well plates or coverslips. In the presence of Lysotracker deep red (Life Technologies, 1:1000) in all conditions, cells were incubated with WT TTR
, and/or FAM-Aβ (500 ng/mL), for 2 hours (for flow cytometry) or 18 hours (for microscopy) and fixed with 4% PFA. Then, Lysotracker inside cells was assessed using flow cytometry analysis, whereas localization of FAM-Aβ and lysosomes was analyzed by fluorescent microscopy (Zeiss Axio Imager Z1, Oberkochen, Germany).
| Protein extraction
Livers from TTR +/+ mice, AD mice with different TTR genetic backgrounds, or AD/TTR+/+ mice treated with IDIF, all with 6-7 months of age, were subjected to protein extraction. Briefly, livers were ho- phenylmethylsulfonyl fluoride (PMSF), and protease inhibitors (GE healthcare), followed by incubation on ice for 20 minutes and centrifugation at 18700 g at 4°C for 20 minutes. Resulting supernatants were used for protein analysis. Total protein concentration was quantified by the Bradford assay (Bio-Rad), using BSA as standard.
| Western blot analysis for LRP1
The expression of LRP1 protein levels was investigated by western blot using liver protein extracts (50 μg) of AD/TTR +/+ (n=4), IDIFtreated AD/TTR+/+ (n=4), and TTR+/+ mice (n=2), aged 6-7 months.
Briefly, proteins were separated either in 10% SDS-PAGE or in 7% tris-acetate PAGE and then transferred to nitrocellulose membrane, and immunoblotting was performed using rabbit anti-LRP1 (Abcam, 1:15000) or mouse anti-β-actin (Sigma-Aldrich, 1:3000).
| Determination of sLRP1 levels
sLRP1 levels in plasma from control and AD mice with different TTR backgrounds, untreated or treated with IDIF, were quantified using sLRP1 ELISA Kit (MyBioSource, San Diego, CA, USA), according to the manufacturer's instructions.
| Statistical analysis
All quantitative data were expressed as mean ± SD and, in case of n ≥ 5, data were expressed as mean ± SEM. Initially, data were assessed whether it followed a Gaussian distribution. When found to follow a 
| RESULTS
| TTR tetrameric structure is less stable in plasma of AD human subjects
As previously described, TTR levels are decreased in AD, not only in the CSF but also in plasma. 8, 20 To assess whether the decrease in TTR concentration in plasmas from patients with AD was due to decreased tetrameric stability, we measured TTR resistance to urea denaturation, as previously described for mice treated with a TTR tetrameric stabilizer. 30 The extent of denaturation of the TTR tetramer was evaluated by measuring how much tetramer or folded TTR (tetramer, trimer, and dimer) and monomer remained after urea treatment.
As it can be seen in Figure 1A , total levels of TTR are lower in AD human plasma compared to the age-matched controls, as also previously showed that TTR stability was also decreased in AD samples compared to controls ( Figure 1A, B) . In other words, significantly higher levels of folded TTR and lower levels of monomer were found in controls, as compared to AD human subjects, suggesting that TTR stability is compromised in AD, followed by decreased levels of TTR in these patients.
| Aβ internalization is increased in the presence of stable WT TTR, but not of L55P TTR
Previous work by our group suggested that the mechanism underlying TTR protection in AD involves TTR participation in Aβ efflux from the brain and uptake at the liver. Interestingly, TTR internalization also varied, as uptake of L55P TTR-633 was observed to be much higher than WT TTR-633, which may be related to higher preference of cells for its degradation, probably due to its unstable conformation. Importantly, higher WT TTR-633 internalization was observed in the presence of FAM-Aβ, which can imply the cointernalization of these two molecules into the cells, while this was not the case for L55P TTR-633. 
| Aβ internalization is increased when L55P TTR is stabilized with IDIF or resveratrol
As previously reported, the effect of TTR stabilizers on the TTR/Aβ interaction is best observed when using unstable TTR mutants. 25 To study the importance of TTR stabilization in Aβ clearance, FAM-Aβ internalization was assessed in the absence or presence of L55P TTR preincubated 
| WT TTR or IDIF-stabilized L55P TTR increases in vitro passage of Aβ through the BBB model
In order to study the importance of TTR stability in Aβ transport across the BBB, hCMEC/D3 cells were cultured in transwells inserts, as depicted in Figure 4A . In this experiment, Aβ was added to basolateral To inspect what happens to TTR during assisted Aβ passage, we measured the amount of labeled TTR in the samples, using fluorimetry. Figure 4C shows the fluorescent intensity of TTR-633 (WT or L55P TTR), present in the blood side or that remained in the brain side. Interestingly, the amount of WT TTR-633 that remained in the brain side was higher than that of L55P TTR-633, which can imply that L55P TTR was degraded more, stayed inside cells, or passed across the monolayer faster than WT TTR-633. According to these results, and considering the possibility of faster passage of L55P TTR-633, its levels in the blood were expected to be higher. However, our results revealed similar amounts of both TTR variants in the compartment mimicking the blood side; therefore, both events, higher degradation (either in the brain or in blood sides) and higher passage, seem to occur at the same time.
Moreover, when L55P TTR-633 was preincubated with IDIF, to promote its stabilization and to perform in a similar fashion to WT TTR, the remained TTR in the brain side was higher than the L55P TTR-633 alone. Accordingly, stabilization with IDIF resulted in lower levels of degradation. Importantly, putting these results together with those of Aβ transport shown in Figure 4B , our data suggest that even if L55P TTR has passed faster through the cell monolayer, it did not assist Aβ passage, while WT TTR or L55P TTR preincubated with IDIF efficiently bound Aβ, assisting its passage and clearance across the cell monolayer. , (e) Fluorescent mean intensity was quantified using ImageJ software using three images from each condition. n=3 for all conditions and data are expressed as mean ± SD. *, #, +, and ^, respectively denote significance from Aβ, Aβ+L55P TTR-633, Aβ+IDIF, and Aβ+WT TTR-633
We also assessed Aβ and TTR levels inside the same monolayer of cells by performing immunostaining and observing the fluorescence using confocal microscopy ( Figure 4 ; the quantification is presented in Figure 4D -e). In the presence of WT TTR-633 ( Figure 4D-b 
| Aβ, in the presence of WT TTR, colocalizes with lysosomes and increases lysosomal activity in HepG2 cells
In order to investigate the fate of Aβ after internalization in HepG2 cells, we used Lysotracker deep red to observe whether FAM-Aβ enters lysosomes for degradation and whether TTR stability plays a determinant role in this process. This result was confirmed by fluorescence microscopy and, as depicted in Figure 5B , when Aβ was coincubated with WT TTR, the colocalization of FAM-Aβ with lysosomes increased. Contrarily, in the presence of L55P TTR, and although the lysosomal activity was higher, colocalization of Aβ with these organelles was not increased. Figure 5C shows a focused image of cells incubated with FAM-Aβ and WT TTR in the presence of Lysotracker and arrows point out yellow dots where Aβ (green) colocalizes with lysosomes (red), indicating higher probability of Aβ degradation, when stable WT TTR is present.
| Levels of LRP1 protein expression increase in the presence of stable TTR
We had previously shown that LRP1 gene and protein expression levels are regulated by TTR.
18 Therefore, to investigate the effect of TTR stability regarding LRP1 expression, we performed immunocyto- ). As presented in Figure 6 , microscopy analysis showed higher levels of LRP1 in the presence of WT TTR, but not in that of L55P TTR, for both cell types.
Furthermore, LRP1 protein levels were increased in brain sections of AD mice treated with IDIF, when compared to nontreated animals.
We also carried out western blot analysis for the liver homogenates from AD/TTR+/+ and IDIF-treated AD/TTR+/+ mice which were available in the laboratory from previous work. 26 As a control, we included nontransgenic mice (TTR+/+), and as expected, these animals showed levels of LRP1 higher than the AD mice ( Figure 7A ).
Importantly, an increase in LRP1 protein levels was observed in the liver homogenates of AD/TTR+/+ mice treated with IDIF when compared to nontreated AD/TTR+/+ mice.
To further investigate the role of LRP1 in TTR-assisted Aβ clearance, we also studied levels of sLRP1 (soluble extracellular domain of LRP1 receptor) in the plasma of mice (AD or non-AD) with different TTR backgrounds or AD/TTR mice treated with IDIF, using an ELISA kit ( Figure 7B, C) . As shown in Figure 7B , unexpectedly, an increase in sLRP1 levels was observed in the plasma of TTR−/− mice compared to TTR +/+ animals. We had previously shown lower levels of LRP1 in the livers of TTR−/− mice, 18 therefore suggesting that the increase in sLRP1 levels reflects an increased shedding of the LRP1 extracellular domain, a mechanism known to occur in the presence of Aβ and pathogenesis of AD, 34 in mouse plasma after LPS treatment, and in human patients with rheumatoid arthritis, 35 suggesting that LRP1
shedding is increased in response to inflammatory processes.
As shown in Figure 7C , IDIF treatment results in a significant increase in plasma sLRP1. However, as already discussed in Figure 7A , IDIF treatment increases also total liver LRP1 levels; thus in this case, sLRP1 levels are elevated not because of the shedding but due to the increased LRP1 expression levels. This further contributes to Aβ clearance, which is increased in IDIF-treated mice, as previously reported,
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suggesting that Aβ binds to sLRP1 in the plasma (preventing its return to the brain) and then uses hepatic LRP1 to be internalized into the liver cells for degradation. Importantly, treatment of AD/TTR−/− mice with IDIF could not increase sLRP1 levels, which confirms that IDIF function is through the stabilization of endogenous TTR. As shown in Figure 7C , the absence of TTR in AD mice, similar to the trend observed in non-AD mice ( Figure 7B ), resulted in increased sLRP1 levels. Therefore, we also performed western blot for LRP1 levels in the livers of AD mice with different TTR background, and as expected, it was observed that TTR reduction coincides with reduction in liver LRP1 levels ( Figure 7D ), confirming that the increase in sLRP1 levels in the absence of TTR in AD mice ( Figure 7C ) was due to LRP1 shedding.
Altogether, these results indicate that TTR reduction decreases liver LRP1 protein level and increases its shedding, resulting in higher plasma sLRP1 levels and, interestingly, IDIF treatment demonstrated both higher hepatic LRP1 and higher plasma sLRP1 levels leading to higher Aβ clearance, through a mechanism that should be further investigated. TTR stabilizer, a natural polyphenol found in grapes, berries, peanuts, and pomegranates, has been shown to reduce neurodegeneration and cognitive decline in mice displaying AD features. 45 This compound was also described to lower the levels of secreted and intracellular Aβ peptides produced from different cell lines, 46 to increase TTR levels 47 and further decrease brain Aβ burden and to increase LRP1 levels in the treated AD animals. 27 Moreover, resveratrol has been demonstrated to increase TTR affinity to Aβ. 25 However, the effect of TTR stabilization has never been specifically studied in Aβ transport and LRP1 levels. Here, we showed that in hCMEC/D3 cells, whereas receptor is susceptible to shedding, which changes its endocytotic activity and, consequently, the clearance of Aβ. For instance, it has been observed that exposure of human brain endothelial cells to Aβ causes shedding of sLRP1. 34 Furthermore, sLRP1 levels are increased in CSF from aged and AD subjects due to shedding. 55 Thus, dysregulation of sLRP1 shedding could impair Aβ clearance, contributing to the pathogenesis of AD. Moreover, a link between inflammation and LRP1 shedding has been demonstrated through the observation of increased sLRP1 levels in mouse plasma after LPS treatment or by macrophages, in vitro, in response to inflammatory mediators, and also in human patients with rheumatoid arthritis and systemic lupus erythematosus. 35 Thus, we assessed the effect of TTR and its stability in sLRP1 levels in the plasma of mice. Although sLRP1 levels were increased in plasma of TTR−/− mice, total LRP1 levels are decreased in the liver of these animals, as previously described, 18 suggesting the measured sLRP1 is mainly a consequence of shedding; the same behavior was also observed in AD mice. As for the impact of IDIF administration, and in spite of the higher levels of sLRP1 in treated animals as compared to controls, total LRP1
| DISCUSSION
was also increased upon treatment, indicating that, in this case, the measured sLRP1 results from an overall increment of the receptor, and not shedding.
Altogether, our results indicate that TTR stability is important for its recently described functions in assisting Aβ transport at the BBB and at the liver and also in regulating LRP1 levels and activity. In conclusion, TTR stabilization can serve as an avenue to increase both Aβ elimination and LRP1 levels, which in turn will further participate in Aβ clearance. These results provide relevant information for the design of TTR-based therapeutic strategies for AD.
